OraSure Technologies, Inc. (OSUR) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the three-month period ended March 31, 2026. OraSure Technologies, Inc. develops, manufactures, and markets diagnostic products and sample management solutions, including tests for HIV, Hepatitis C, Syphilis, Sickle Cell, and COVID-19. The company operates as a single reportable segment. As of April 30, 2026, there were 68,848,553 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Revenues | $27.9 million | $29.9 million |
| Gross Profit | $11.8 million | $12.3 million |
| Gross Margin | 42.3% | 41.1% |
| Operating Loss | $(23.3) million | $(17.8) million |
| Net Loss | $(22.4) million | $(16.0) million |
| Loss Per Share (Diluted) | $(0.32) | $(0.21) |
| Cash and Cash Equivalents | $177.0 million | $247.6 million |
| Working Capital | $196.7 million | N/A |
| Net Cash Used in Operating Activities | $(13.9) million | $(19.7) million |
Material Changes vs. Prior Period
- Revenue Decline: Net revenues decreased 7% year-over-year. This was driven by a 5% drop in Diagnostics revenue (primarily lower international HCV sales) and a 96% collapse in COVID-19 diagnostics revenue due to contract completion. The Risk Assessment Testing line was fully discontinued, eliminating $1.4 million in prior-year revenue.
- Increased Operating Loss: The operating loss widened by $5.5 million to $23.3 million. This was primarily caused by a 42% increase in Research and Development (R&D) expenses to $13.7 million, driven by clinical trials for new CT/NG and Colli-Pee devices, alongside severance charges from a Q1 2026 workforce reduction.
- Margin Expansion: Despite lower revenues, gross margin improved to 42.3% due to better absorption of fixed overhead, improved product mix, and higher non-product revenues (which carry 100% margin).
- Share Repurchases: The company repurchased 1.8 million shares for $5.0 million under its authorized program, reducing cash balances.
Guidance, Outlook, and Risks
- Outlook: Management expects existing cash ($177 million) to fund operations and capital expenditures for the next 12 months. No specific financial guidance for the full year 2026 was provided in this text.
- Strategic Initiatives: The company is advancing clinical trials for a rapid molecular self-test for CT/NG and the Colli-Pee urine collection device, both of which have 510(k) submissions under FDA review. The company also acquired BioMedomics in late 2025 to add the SickleSCAN test to its portfolio.
- Risks and Contingencies:
- Litigation: OraSure is engaged in ongoing litigation against NowDiagnostics, Inc. and former employees regarding trade secret misappropriation. A trial is scheduled for January 17, 2027.
- Regulatory: Future performance depends on obtaining regulatory approvals for new products and maintaining compliance with FDA requirements.
- Market Conditions: Risks include customer concentration, reliance on sole-supply vendors, and potential negative impacts from geopolitical or economic conditions.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $13.9 million quarterly operating cash burn against the $177 million cash balance, considering the high R&D spend.
- R&D ROI: Assess the timeline and probability of FDA approval for the CT/NG and Colli-Pee devices to justify the 42% increase in R&D expenses.
- Revenue Mix: Monitor the trajectory of HCV and Syphilis sales to determine if the decline in HCV is a temporary ordering issue or a structural market shift.
- Legal Exposure: Track the discovery phase of the NowDiagnostics litigation for potential financial impact or operational disruption.
- Acquisition Integration: Review the performance of the BioMedomics acquisition (SickleSCAN) to ensure it meets the sales thresholds required for contingent consideration payments.